Options Bears Break Bank With Biotech Stock Puts

Multiple layers of resistance were pressuring ImmunoGen stock

Deputy Editor
Aug 8, 2023 at 3:11 PM
facebook twitter linkedin

Subscribers to Schaeffer's Event Trader service scored a 272% profit with our  ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation. Below, we will take a closer look at why IMGN was on our radar, and how the trade ultimately unfolded.

We recommended the ImmunoGen trade on Aug. 2. At that time, the biotech stock had run into resistance at its 20-day moving average and broken below its 50-day trendline following second-quarter earnings. The $19 area also rejected IMGN, and is home to a 38.2% retracement of its 2000 highs and 2016 lows. 

The security was also ripe for a round of analyst downgrades. This is per the nine of 11 covering brokerages that called ImmunoGen stock a "strong buy," against two "hold" ratings.

Plus, options traders were more call-heavy than usual. At the time, IMGN's 10-day put/call volume ratio over at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sat higher than 14% of readings from the past year. This implies options traders favored bullish bets over the previous two weeks.

The day after our put recommendation, ImmunoGen stock dropped nearly 3.5%. The stock settled near the $14 level by the time we closed our position on Monday, Aug. 7 following a 16% dip, allowing our subscribers to lock in a 272% profit in less than a week.

IMGN Chart 2 August 82023


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!